Gabapentin Therapy for Amyotrophic Lateral Sclerosis: Lack of Improvement in Neuronal Integrity Shown by MR Spectroscopy

References

1. ↵
   Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995;68:7–20

   PubMedWeb of Science
2. ↵
   Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233–249

   CrossRefPubMedWeb of Science
3. ↵
   Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995;65:643–651

   PubMedWeb of Science
4. ↵
   Eisen A. Corticospinal motor neurons: pathophysiology. In: Brown RHJ, Meininger V, Swash M, eds. Amyotrophic Lateral Sclerosis. London: Martin Dunitz, Ltd.2000;161–177
5. ↵
   Caramia MD, Palmieri MG, Desiato MT, et al. Pharmacologic reversal of cortical hyperexcitability in patients with ALS. Neurology 2000;54:58–64

   Abstract/FREE Full Text
6. ↵
   Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147–157

   CrossRefPubMedWeb of Science
7. ↵
   Romano JG. Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin. Arch Neurol 1996;53:716

   CrossRefPubMed
8. ↵
   Serrao M, Rossi P, Cardinali P, Valente G, Parisi L, Pierelli F. Gabapentin treatment for muscle cramps: an open-label trial. Clin Neuropharmacol 2000;23:45–49

   CrossRefPubMed
9. ↵
   Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis: WALS Study Group—Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996;47:1383–1388

   Abstract/FREE Full Text
10. ↵
    Mazzini L, Mora G, Balzarini C, et al. The natural history and the effects of gabapentin in amyotrophic lateral sclerosis. J Neurol Sci 1998;160(suppl)1:S57–S63
11. ↵
    Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843–848

    FREE Full Text
12. ↵
    Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37–45

    CrossRefPubMedWeb of Science
13. ↵
    Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991;2:131–134

    PubMedWeb of Science
14. ↵
    Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994;44:1933–1938

    Abstract/FREE Full Text
15. Jones AP, Gunawardena WJ, Coutinho CM, Gatt JA, Shaw IC, Mitchell JD. Preliminary results of proton magnetic resonance spectroscopy in motor neuron disease (amyotrophic lateral sclerosis). J Neurol Sci 1995;129(suppl):85–89
16. Rooney WD, Miller RG, Gelinas D, Schuff N, Maudsley AA, Weiner MW. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 1998;50:1800–1805

    Abstract/FREE Full Text
17. ↵
    Block W, Karitzky J, Traber F, et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol 1998;55:931–936

    CrossRefPubMedWeb of Science
18. Ellis CM, Simmons A, Andrews C, Dawson JM, Williams SC, Leigh PN. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology 1998;51:1104–1109

    Abstract/FREE Full Text
19. ↵
    Chan S, Shungu DC, Douglas-Akinwande A, Lange DJ, Rowland LP. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 1999;212:763–769

    PubMedWeb of Science
20. ↵
    Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757–1761

    PubMedWeb of Science
21. ↵
    Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis: Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 1994;124(suppl):96–107
22. ↵
    Parent A. Carpenter’s Human Neuroanatomy. 9th ed. Baltimore: Lippincott Williams & Wilkins;1996 :864–936
23. ↵
    Martin JE, Swash M. The pathology of motor neuron disease. In: Leigh PN, Swash M, eds. Motor Neuron Disease, Biology and Management. London: Springer-Verlag;1995 :93–118
24. ↵
    De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721–727

    PubMedWeb of Science
25. Uno M, Ueda S, Hondo H, Matsumoto K, Harada M. Effectiveness of revascularization surgery evaluated by proton magnetic resonance spectroscopy and single photon emission computed tomography. Neurologia Medico-Chirurgica 1996;36:560–566

    CrossRef
26. Cendes F, Andermann F, Dubeau F, Matthews PM, Arnold DL. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology 1997;49:1525–1533

    Abstract/FREE Full Text
27. Vion-Dury J, Nicoli F, Salvan AM, Confort-Gouny S, Dhiver C, Cozzone PJ. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet 1995;345:60–61

    PubMed
28. ↵
    Moore GJ, Bebchuk JM, Hasanat K, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? Biological Psychiatry 2000;48:1–8

    CrossRefPubMedWeb of Science
29. ↵
    Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425–1431

    PubMedWeb of Science
30. ↵
    Vielhaber S, Kaufmann J, Kanowski M, et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol 2001;172:377–382

    CrossRefPubMedWeb of Science
31. ↵
    Bowen BC, Pattany PM, Bradley WG, et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2000;21:647–658

    Abstract/FREE Full Text
32. ↵
    Kalra S, Caramanos Z, Cashman N, Genge A, Arnold DL. MRSI demonstrates lack of improvement in corticoneuronal integrity with gabapentin therapy in ALS. CJNS 2000;27:S18
33. ↵
    Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2000;55:S41–S46
34. ↵
    Hudson AJ. Pain perception and response: central nervous system mechanisms. Can J Neurol Sci 2000;27:2–16

    PubMedWeb of Science
35. ↵
    Pohl C, Block W, Karitzky J, et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol 2001;58:729–735

    CrossRefPubMedWeb of Science
36. ↵
    Gredal O, Rosenbaum S, Topp S, Karlsborg M, Strange P, Werdelin L. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997;48:878–881

    Abstract/FREE Full Text
37. ↵
    Sarchielli P, Pelliccioli GP, Tarducci R, et al. Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001;43:189–197

    CrossRefPubMedWeb of Science